IMMX Logo

Immix Biopharma, Inc. (IMMX) 

NASDAQ
Market Cap
$58.32M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
279 of 958
Rank in Industry
168 of 549

Largest Insider Buys in Sector

IMMX Stock Price History Chart

IMMX Stock Performance

About Immix Biopharma, Inc.

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply …

Insider Activity of Immix Biopharma, Inc.

Over the last 12 months, insiders at Immix Biopharma, Inc. have bought $132,220 and sold $0 worth of Immix Biopharma, Inc. stock.

On average, over the past 5 years, insiders at Immix Biopharma, Inc. have bought $304,910 and sold $550 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Hsu Jason (director) — $71,140. Morris Gabriel S (CFO) — $21,312. Rachman Ilya M (CEO and Chairman) — $21,168.

The last purchase of 8,100 shares for transaction amount of $18,233 was made by Hsu Jason (director) on 2024‑08‑22.

List of Insider Buy and Sell Transactions, Immix Biopharma, Inc.

2024-08-22Purchasedirector
8,100
0.0301%
$2.25$18,233-18.78%
2024-08-21Purchasedirector
15,000
0.0533%
$2.23$33,390-21.05%
2024-08-16Purchasedirector
10,000
0.0379%
$1.86$18,6000.00%
2024-07-24Purchasedirector
6,000
0.0237%
$2.15$12,8770.00%
2024-07-18Purchasedirector
3,200
0.0123%
$2.07$6,639-7.32%
2024-06-07PurchaseCEO and Chairman
2,600
0.0103%
$2.13$5,538-1.23%
2024-06-07PurchaseCFO
2,500
0.0099%
$2.12$5,298-1.23%
2024-06-04PurchaseCEO and Chairman
3,300
0.0125%
$1.81$5,970+10.44%
2024-06-04PurchaseCFO
3,300
0.0125%
$1.81$5,973+10.44%
2024-05-14PurchaseCEO and Chairman
4,300
0.0166%
$2.25$9,660-7.27%
2024-05-14PurchaseCFO
4,500
0.0173%
$2.23$10,042-7.27%
2023-12-11Purchasedirector
31,000
0.1596%
$4.67$144,894-51.96%
2023-12-08Purchasedirector
25,000
0.1278%
$4.88$122,025-54.62%
2023-09-15Purchasedirector
7,000
0.04%
$2.49$17,396+12.36%
2023-09-14Purchasedirector
10,000
0.0623%
$2.58$25,772+17.91%
2023-09-14Purchasedirector
10,000
0.0623%
$2.58$25,760+17.91%
2023-09-12Purchasedirector
30,000
0.1874%
$2.83$84,864+7.55%
2023-09-12Purchasedirector
13,000
0.085%
$2.96$38,492+7.55%
2023-09-11Purchasedirector
25,000
0.1563%
$2.89$72,280+5.28%
2023-09-08Purchasedirector
10,000
0.0596%
$2.53$25,317+14.75%

Insider Historical Profitability

<0.0001%
Rachman Ilya MCEO and Chairman
1136259
4.1307%
$2.1250+36.38%
Hsu Jasondirector
845300
3.073%
$2.12120<0.0001%
Morris Gabriel SCFO
285834
1.0391%
$2.1250+36.38%
Ng Careydirector
20000
0.0727%
$2.1230<0.0001%
Torchilin Vladimir PScientific Co-Founder
905200
3.2907%
$2.1220<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.